Literature DB >> 7517875

Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells in vitro.

R N Barker1, C J Elson.   

Abstract

The extent of autoreactive T cell repertoire in the normal individual has previously been unclear. Here we demonstrate that T cells from healthy humans can be stimulated by multiple epitopes on a self protein to give primary proliferative responses in vitro. Synthetic 15-mer peptides, corresponding to the sequence of a human red blood cell Rhesus polypeptide, were tested for the ability to stimulate normal T cells. Multiple peptides were found to provoke responses reproducibly, and the proliferation could be blocked consistently by antibodies to HLA-DR, but not -DP or -DQ. T cells from each donor proliferated in response to different patterns of peptides, but this variation in pattern was less marked in individuals with the same HLA-DR type. The responses were comparable in kinetics to those elicited by the non-recall foreign antigen keyhole limpet hemocyanin, and the responding cells are most commonly derived from the CD45RA+ subpopulation, indicating that they had not been activated in vivo. It is considered that T cells are "immunologically ignorant" of many self peptides, presumably because they correspond to cryptic epitopes that are not normally presented in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517875     DOI: 10.1002/eji.1830240719

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Healthy individuals have Goodpasture autoantigen-reactive T cells.

Authors:  Juan Zou; Sigrid Hannier; Lindsay S Cairns; Robert N Barker; Andrew J Rees; A Neil Turner; Richard G Phelps
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

2.  Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions.

Authors:  B J Lewis; S Rajpara; A M Haggart; H M Wilson; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

3.  Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis.

Authors:  M Ponsford; G Mazza; J Coad; M J Campbell; J Zajicek; D C Wraith
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

4.  Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia.

Authors:  Andrew M Hall; Omar M Zamzami; Natasha Whibley; Daniel P Hampsey; Anne M Haggart; Mark A Vickers; Robert N Barker
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

5.  Ability of T cells from patients with rheumatoid arthritis to respond to immunoglobulin G.

Authors:  A K Lang; L M Macht; J R Kirwan; D C Wraith; C J Elson
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

6.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

7.  T-helper 1 dominated responses to erythrocyte Band 3 in NZB mice.

Authors:  C R Shen; G Mazza; F E Perry; J T Beech; S J Thompson; A Corato; S Newton; R N Barker; C J Elson
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

8.  Effect of T-helper cytokine environment on specificity of T-cell responses to mycobacterial 65,000 MW heat-shock protein.

Authors:  L K Siew; J T Beech; S J Thompson; C J Elson
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

9.  Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody.

Authors:  M Kuwana; J Kaburaki; Y Ikeda
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 10.  Autoimmune Hemolysis: A Journey through Time.

Authors:  John Freedman
Journal:  Transfus Med Hemother       Date:  2015-08-10       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.